<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03645642</url>
  </required_header>
  <id_info>
    <org_study_id>ILBS-Cirrhosis-18</org_study_id>
    <nct_id>NCT03645642</nct_id>
  </id_info>
  <brief_title>To Study the Safety and Efficacy of Midodrine With Albumin Versus Albumin Alone in Hepatic Hydrothorax</brief_title>
  <official_title>To Study the Safety and Efficacy of Midodrine With Albumin Versus Albumin Alone in Hepatic Hydrothorax- A Pilot Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Liver and Biliary Sciences, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Liver and Biliary Sciences, India</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatic hydrothorax is defined with accumulation of transudate fluid (500 ml) in the pleural
      cavity in patients with decompensated liver cirrhosis but without cardiopulmonary and pleural
      diseases. The Prevalence is 5-12% The treatment for hydrothorax is diuretics, repeated
      thoracocentensis, TIPS and liver transplant.. Midodrine increases effective arterial blood
      volume and also increases renal perfusion.It has also been used in Refractory ascitis .It has
      been shown to mobilise ascitis. In patients who are ineligible for TIPS and Liver transplant
      there is no data on Midodrine and its effects on Hydrothorax in cirrhotics.There are also no
      guidelines on the use of albumin during Pleural fluid tapping and the dose to be used. This
      study is being done to assess the safety and efficacy of Midodrine in hydrothorax.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 30, 2018</start_date>
  <completion_date type="Actual">December 31, 2018</completion_date>
  <primary_completion_date type="Actual">December 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in frequency of thoracentesis.</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Partial or complete resolution of hepatic hydrothorax</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of Spontaneous Bacterial Empyema</measure>
    <time_frame>3 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of Thorocacocentesis Induced circulatory dysfunction</measure>
    <time_frame>3 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug related adverse events in both arms</measure>
    <time_frame>3 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transplant free survival in both groups</measure>
    <time_frame>3 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictors and mechanisms of repeated development of hepatic hydrothorax</measure>
    <time_frame>3 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients going for TIPS(Transintrahepatic Portosystemic Shunts)</measure>
    <time_frame>3 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Hepatic Hydrothorax</condition>
  <arm_group>
    <arm_group_label>Midodrine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Midodrine (5 mg TDS) along with albumin(20g/l) and diuretics. The dose of Midodrine will titrated according to the Mean arterial pressure (75-90mmhg). The dose will be increased to a maximum of 12.5 mg thrice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Albumin with diuretics</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Albumin(20g/l) and diuretics.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midodrine</intervention_name>
    <description>Midodrine 5 mg thrice daily</description>
    <arm_group_label>Midodrine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Albumin</intervention_name>
    <description>Albumin 20g/l</description>
    <arm_group_label>Albumin with diuretics</arm_group_label>
    <arm_group_label>Midodrine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diuretics</intervention_name>
    <description>Diuretics will be continued with an maximum dose of furosemide (160mg) and Aldactone 400 mg.</description>
    <arm_group_label>Albumin with diuretics</arm_group_label>
    <arm_group_label>Midodrine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with hepatic hydrothorax

          -  Patients with age from 18-75 years

          -  No evidence of Cardiac and pulmonary disease

        Exclusion Criteria:

          -  Renal failure ( Creatinine&gt;2.5mg/dl)

          -  Gastrointestinal bleeding

          -  Spontaneous bacterial empyema/ Peritonitis

          -  Patients with urinary retention

          -  Intrinsic advanced pulmonary disease (CXR, HRCT thorax)

          -  Cardiovascular disease (Electrocardiogram, 2D Echo)

          -  Systemic arterial hypertension

          -  Presence of hepatocellular carcinoma or portal vein thrombosis, Budd chiari syndrome

          -  Patients with active untreated sepsis

          -  Pregnancy

          -  Patients with hepatic encephalopathy

          -  Patients eligible for TIPS

          -  No use of drugs affecting systemic hemodynamics prior to 7 day of enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institute of Liver and Biliary Sciences</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110070</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>August 22, 2018</study_first_submitted>
  <study_first_submitted_qc>August 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2018</study_first_posted>
  <last_update_submitted>June 23, 2020</last_update_submitted>
  <last_update_submitted_qc>June 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrothorax</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midodrine</mesh_term>
    <mesh_term>Diuretics</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

